Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
14
04
2020
accepted:
18
08
2020
pubmed:
7
10
2020
medline:
29
1
2021
entrez:
6
10
2020
Statut:
ppublish
Résumé
Comprehensive genomic profiling enables genomic biomarker detection in advanced solid tumors. Here, to evaluate the utility of circulating tumor DNA (ctDNA) genotyping, we compare trial enrollment using ctDNA sequencing in 1,687 patients with advanced gastrointestinal (GI) cancer in SCRUM-Japan GOZILA (no. UMIN000016343), an observational ctDNA-based screening study, to enrollment using tumor tissue sequencing in the same centers and network (GI-SCREEN, 5,621 patients). ctDNA genotyping significantly shortened the screening duration (11 versus 33 days, P < 0.0001) and improved the trial enrollment rate (9.5 versus 4.1%, P < 0.0001) without compromising treatment efficacy compared to tissue genotyping. We also describe the clonal architecture of ctDNA profiles in ~2,000 patients with advanced GI cancer, which reinforces the relevance of many targetable oncogenic drivers and highlights multiple new drivers as candidates for clinical development. ctDNA genotyping has the potential to accelerate innovation in precision medicine and its delivery to individual patients.
Identifiants
pubmed: 33020649
doi: 10.1038/s41591-020-1063-5
pii: 10.1038/s41591-020-1063-5
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
DNA, Neoplasm
0
Banques de données
JPRN
['UMIN000016343']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1859-1864Commentaires et corrections
Type : CommentIn
Références
Bando, H. The current status and problems confronted in delivering precision medicine in Japan and Europe. Curr. Probl. Cancer 41, 166–175 (2017).
doi: 10.1016/j.currproblcancer.2017.02.003
Spiegel, M. L. et al. Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. Cancer 123, 4800–4807 (2017).
doi: 10.1002/cncr.31056
Lim, C. et al. Patients with advanced non-small cell lung cancer: are research biopsies a barrier to participation in clinical trials? J. Thorac. Oncol. 11, 79–84 (2016).
doi: 10.1016/j.jtho.2015.09.006
Nakamura, Y. & Yoshino, T. Clinical utility of analyzing circulating tumor DNA in patients with metastatic colorectal cancer. Oncologist 23, 1310–1318 (2018).
doi: 10.1634/theoncologist.2017-0621
Nakamura, Y. & Shitara, K. Development of circulating tumour DNA analysis for gastrointestinal cancers. ESMO Open 5, e000600 (2020).
doi: 10.1136/esmoopen-2019-000600
Rothwell, D. G. et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat. Med. 25, 738–743 (2019).
doi: 10.1038/s41591-019-0380-z
Strickler, J. H. et al. Genomic landscape of cell-free DNA in patients with colorectal cancer. Cancer Discov. 8, 164–173 (2018).
doi: 10.1158/2159-8290.CD-17-1009
Maron, S. B. et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin. Cancer Res. 25, 7098–7112 (2019).
doi: 10.1158/1078-0432.CCR-19-1704
Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).
doi: 10.1186/s13073-017-0424-2
Salem, M. E. et al. Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. Mol. Cancer Res. 16, 805–812 (2018).
doi: 10.1158/1541-7786.MCR-17-0735
Meric-Bernstam, F. et al. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann. Oncol. 27, 795–800 (2016).
doi: 10.1093/annonc/mdw018
Nance, T. et al. Abstract 4272: a novel approach to differentiation of somatic vs. germline variants in liquid biopsies using a betabinomial model. Cancer Res. 78, 4272 (2018).
Golan, T. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. 381, 317–327 (2019).
doi: 10.1056/NEJMoa1903387
Golan, T. et al. Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study. Oncologist 22, 804–810 (2017).
doi: 10.1634/theoncologist.2016-0415
Parikh, A. R. et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat. Med. 25, 1415–1421 (2019).
doi: 10.1038/s41591-019-0561-9
Network, C. G. A. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
doi: 10.1038/nature11252
Zhang, L. & Shay, J. W. Multiple roles of APC and its therapeutic implications in colorectal cancer. J. Natl Cancer Inst. 109, djw332 (2017).
doi: 10.1093/jnci/djw332
The Cancer Genome Atlas Research Networket al. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017).
doi: 10.1038/nature20805
Deng, J. et al. Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations. Nat. Commun. 8, 1533 (2017).
doi: 10.1038/s41467-017-01730-x
The Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185–203 (2017).
Banales, J. M. et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat. Rev. Gastroenterol. Hepatol. 13, 261–280 (2016).
doi: 10.1038/nrgastro.2016.51
Abou-Alfa, G. K. et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 21, 796–807 (2020).
doi: 10.1016/S1470-2045(20)30157-1
Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med. 381, 1632–1643 (2019).
doi: 10.1056/NEJMoa1908075
Li, S., Balmain, A. & Counter, C. M. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat. Rev. Cancer 18, 767–777 (2018).
doi: 10.1038/s41568-018-0076-6
Thompson, J. C. et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin. Cancer Res. 22, 5772–5782 (2016).
doi: 10.1158/1078-0432.CCR-16-1231
Villaflor, V. et al. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget 7, 66880–66891 (2016).
doi: 10.18632/oncotarget.11801
Aggarwal, C. et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 5, 173–180 (2019).
doi: 10.1001/jamaoncol.2018.4305
Leighl, N. B. et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin. Cancer Res. 25, 4691–4700 (2019).
doi: 10.1158/1078-0432.CCR-19-0624
Lih, C. J. et al. Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: molecular analysis for therapy choice clinical trial. J. Mol. Diagn. 19, 313–327 (2017).
doi: 10.1016/j.jmoldx.2016.10.007
Odegaard, J. I. et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clin. Cancer Res. 24, 3539–3549 (2018).
doi: 10.1158/1078-0432.CCR-17-3831
Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at https://arxiv.org/abs/1303.3997 (2013).
Willis, J. et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. Clin. Cancer Res. 25, 7035–7045 (2019).
doi: 10.1158/1078-0432.CCR-19-1324
Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. https://ascopubs.org/doi/10.1200/PO.17.00011 (2017).
Hu, Y. et al. Discrimination of germline EGFR T790M mutations in plasma cell-free DNA allows study of prevalence across 31,414 cancer patients. Clin. Cancer Res. 23, 7351–7359 (2017).
doi: 10.1158/1078-0432.CCR-17-1745